Genmab A/S Sponsored ADR $GMAB Stock: Perpetual Ltd Reduces Stake

Perpetual Ltd lessened its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 21.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 718,179 shares of the company’s stock after selling 200,869 shares during the period. Perpetual Ltd’s holdings in Genmab A/S were worth $25,621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 20.5% during the third quarter. GAMMA Investing LLC now owns 4,792 shares of the company’s stock valued at $171,000 after acquiring an additional 814 shares in the last quarter. Juncture Wealth Strategies LLC lifted its position in Genmab A/S by 42.0% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 10,424 shares of the company’s stock worth $372,000 after acquiring an additional 3,083 shares during the period. Versant Capital Management Inc boosted its position in Genmab A/S by 4.5% in the third quarter. Versant Capital Management Inc now owns 12,235 shares of the company’s stock valued at $436,000 after buying an additional 523 shares during the last quarter. QRG Capital Management Inc. boosted its holdings in shares of Genmab A/S by 10.4% in the 2nd quarter. QRG Capital Management Inc. now owns 72,643 shares of the company’s stock valued at $1,996,000 after acquiring an additional 6,821 shares during the last quarter. Finally, WINTON GROUP Ltd boosted its holdings in Genmab A/S by 158.9% in the second quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock valued at $1,124,000 after purchasing an additional 25,100 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Up 0.8%

Shares of NASDAQ:GMAB opened at $37.37 on Tuesday. Genmab A/S Sponsored ADR has a 52 week low of $23.62 and a 52 week high of $40.17. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The company has a market cap of $23.32 billion, a PE ratio of 29.43, a P/E/G ratio of 1.72 and a beta of 0.81. The company’s 50 day moving average is $33.78 and its two-hundred day moving average is $29.46.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. Equities analysts predict that Genmab A/S Sponsored ADR will post 1.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on GMAB. Truist Financial lifted their price objective on shares of Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Guggenheim lifted their target price on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. HC Wainwright increased their price target on Genmab A/S from $40.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Finally, TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $32.00 to $43.00 in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.